Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo ReNi II: Neoadjuvant Relatlimab and Nivolumab in High Risk Stage II Melanoma
NCT05418972Phase 2Active, not recruiting
- Sponsor
- Melanoma Institute Australia
- Start
- Aug 2023
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of relatlimab, nivolumab in melanoma, sponsored by Melanoma Institute Australia. Started Aug 2023; status: active, not recruiting.
02
Drugs
relatlimabnivolumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05418972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05418972.